Table 1.

CETP inhibitors: clinical trials and cardiovascular outcomes.

Ref.	CETP Inhibitor	Trial	Patients	Duration	Effect on Lipids in Treatment Group	CV Results
Barter PJ. N. Engl. J. Med. 2007 [66]	Torcetrapib	ILLUMINATE	15,067 patients at high cardiovascular risk	1–2 years	HDL-C: +72% LDL-C: −25%	Increased risk of cardiovascular events (HR 1.25; 95%CI 1.09–1.44; p = 0.001) and death from any cause (HR 1.58; 95%CI 1.14–2.19; p = 0.006)
Schwartz GG. N. Engl. J. Med. 2012 [42]	Dalcetrapib	Dal-OUTCOMES	15,871 patients recently hospitalized for acute coronary syndrome	31 months (stopped early for futility)	HDL-C: 31 to 40% minimal effect on LDL-C	No effect on the CV composite endpoint (HR 1.04; 95%CI 0.93–1.16; p = 0.52)
Lincoff AM. N. Engl. J. Med. 2017 [47]	Evacetrapib	ACCELERATE	12,092 patients at high cardiovascular risk	26 months (stopped early for futility)	HDL-C: +133% LDL-C: −31%	No effect on the CV composite endpoint (HR 1.01; 95%CI 0.91–1.11; p = 0.91)
Bowman L. N. Engl. J. Med. 2017 [67]	Anacetrapib	REVEAL	30,449 patients at high cardiovascular risk	4.1 years	HDL-C: +104% LDL-C: −26%	Decrease in the CV composite endpoint (HR 0.91; 95%CI 0.85–0.97; p = 0.004)

HR: hazard ratio.